Prot #INS1007-301: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study

Project: Research project

Project Details

StatusActive
Effective start/end date12/16/21 → 12/16/24

Funding

  • PPD Development ((OE) Prot #INS1007-301 // (OE) Prot #INS1007-301)
  • Insmed Incorporated ((OE) Prot #INS1007-301 // (OE) Prot #INS1007-301)